Thus, in the context of combination treatment, arsenic sulfide inhibits THBS1 in tumor cells while upregulating CD69 and downregulating LAG3 in T cells, it is reasonable to surmise that arsenic sulfide modulates T cell activity to augment the efficacy of anti-PD-1 therapy. The gene discussed is RPL17; the disease is neoplasm.